Research programme: neuronal nitric oxide synthase inhibitors - AstraZeneca

Drug Profile

Research programme: neuronal nitric oxide synthase inhibitors - AstraZeneca

Alternative Names: Neuronal nitric oxide synthase inhibitors research programme - AstraZeneca

Latest Information Update: 24 Aug 2006

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 24 Aug 2006 Discontinued - Preclinical for Parkinson's disease in Sweden (unspecified route)
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 11 Feb 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top